Arsenic trioxide inhibits p-glycoprotein expression in multidrug-resistant human leukemia cells that overexpress the MDR1 gene

Area of Science:

• Hematology
• Molecular Biology
• Cancer Research

Background:

• Multidrug resistance (MDR) in leukemia poses a significant therapeutic challenge.
• Overexpression of P-glycoprotein (P-gp) is a key mechanism contributing to MDR in leukemia.
• Arsenic trioxide (As(2)O(3)) has shown promise in cancer therapy, but its effects on MDR leukemia require further investigation.

Purpose of the Study:

• To evaluate the impact of arsenic trioxide (As(2)O(3)) on apoptosis induction in multidrug-resistant human leukemia cells.
• To assess the effect of As(2)O(3) on P-glycoprotein (P-gp) expression in these cells.
• To determine the synergistic potential of As(2)O(3) in combination with adriamycin against drug-resistant leukemia.

Main Methods:

• Utilized the human multidrug-resistant leukemia cell line K562/ADM, known for MDR1 gene overexpression.
• Assessed cell proliferation using MTT assays and cytomorphology via light, confocal, and electron microscopy.
• Analyzed DNA fragmentation, P-gp expression, cell cycle status, and sub-G1 populations using agarose gel electrophoresis and flow cytometry.

Main Results:

• As(2)O(3) (0.5–20 µmol/L) inhibited K562/ADM cell proliferation, demonstrating greater sensitivity compared to parental K562 cells.
• Morphological changes, DNA laddering, and increased sub-G1 populations confirmed As(2)O(3)-induced apoptosis.
• Significant downregulation of P-gp expression was observed, leading to enhanced sensitivity to adriamycin.

Conclusions:

• Arsenic trioxide induces significant growth inhibition and apoptosis in multidrug-resistant leukemia cells.
• As(2)O(3) effectively down-regulates P-gp expression, a crucial factor in overcoming multidrug resistance.
• A synergistic effect was observed when As(2)O(3) was combined with adriamycin, suggesting a promising therapeutic strategy.